anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Strabismus surgery can cause unfavorable side effects during intraoperative and postoperative periods including increased risk of the oculocardiac reflex, hemodynamic instability, emergence agitation, postoperative pain, nausea and vomiting. Sevoflurane is an inhalation anesthetic widely used in pediatric anesthesia with minimal airway irritation. Propofol is an intravenous sedative-hypnotic agent with amnestic properties that causes loss of consciousness. Bispectral index monitor provide some more evidence that deeper anesthesia can provide some protection against the oculocardiac reflex. Therefore, this study is conducted to evaluate the role of BIS monitoring in comparing the use of propofol and sevoflurane anesthesia in pediatric strabismus surgery.

This prospective, randomized, comparative clinical study will include 100 children who are scheduled for elective strabismus surgery under general anesthesia in Mansoura ophthalmology center. Informed written consent is obtained from parents of all subjects in the study after ensuring confidentiality. The study protocol is explained to parents of all patients in the study who are kept fasting prior to surgery. Patients are randomly assigned to two equal groups according to computer-generated table of random numbers using the permuted block randomization method. The collected data are coded, processed, and analyzed using SPSS program. All data are considered statistically significant if P value is ≤ 0.05.
The invention provides an IgE and antigen-specific screening assay for use in identifying agents which suppress the IgE mediated immune response to antigen. The assay is performed in vivo in Animals which hyper respond to antigen by producing exaggerated levels of IgE. The animals are sensitized to an antigen during a specific window of sensitivity which closes a day after the animal has been treated to produce the IgE hyper responsive phenotype.  The screening assay is performed in the animals by treating them with a candidate IgE suppressor agent in conjunction with further immunization made after closure of the window of sensitivity defined by the invention. Positive results (indicating that the candidate agent has IgE suppressive activity) are obtained in the assay through measurement of a decline in antigen-specific IgE in the animal following its treatment with the candidate agent. The screening assay may also be utilized to measure other components of the immune response to antigen, including IgG1 and IgG2a antibody production.
All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
The study consists of three phases for development and evaluation of the SMART portal. Phase 1 is the development of online assessments and intervention components. There will be no participant interaction with the portal during Phase 1. Phase 2 will consist of one, individual interview with patients, caregivers, and clinicians/nurses to interact with a portal prototype and provide feedback. Phase 3 will contain an open trial for patients and caregivers with baseline, 2-6 months interacting with the portal and progressing through applicable intervention components, and post-treatment. Patient test data will also be loaded into the portal during Phase 3 for clinicians/nurses to interact with for 2-6 months. Feedback from all users will be collected at post-treatment for optimization of the portal.
<P>PROBLEM TO BE SOLVED: To provide a receiver preventing that, when energization to the receiver is stopped, a user unknowing it uselessly tries to transmit measurement information of respective measuring instruments to the receiver.  <P>SOLUTION: The receiver 11 receives generated measurement information from the measuring instruments 12a-12c for generating measurement information by measuring the body state or motion on the health, and transmits the received measurement information to a management server 20 for managing the measurement information. At stopping the energization when the energization from a secondary power supply 11d for regularly supplying the power to the inside of a body 11g, to the body 11g is stopped, a backup power supply 11e of the receiver 11 starts to supply the power to the body 11b as a substitute for the secondary power supply 11d. A control section 11a and a second communication processing section 11c, when stopping the energization, control to notify the stop of the energization to the management server 20. An operator of the management server 20 reports the stop of the energization to the receiver 11 to users by an appropriate communication means.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Cerebral metastases are a major public health problem in cancer patients. They are the most common brain tumours in adults. It is estimated that approximately 20-40% of patients with primary malignant neoplasia will develop cerebral metastasis during the course of their illness. In addition, the incidence of brain metastases is increasing due, in particular, to the aging of the population, as well as to the improvement of the overall management of cancer patients (cytotoxic or targeted systemic treatment) and easier access to magnetic resonance imaging (MRI), which improves patient survival. The prognosis of patients with brain metastases is still poor and the median overall survival of these patients is of the order of a few months. Although the management of brain metastases is multidisciplinary, the benefit of surgery has been clearly demonstrated in the literature. Consequently, it is demonstrated that the quality of the tumour excision and in particular the carrying out of the complete excision of contrast enhancement on the MRI is correlated with improved overall survival (especially in case of single metastasis) and improved local control of the disease or progression-free survival, but also a better quality of life. It is therefore essential to perform the most complete excision possible while minimising the associated morbidity. For this purpose, various tools for surgical resection have been developed and are available, including intraoperative fluorescence guided surgery. Sodium fluorescein is a fluorochrome that accumulates, after intravenous injection, into vascularised tumour tissues and is revealed intraoperatively by a light source of suitable wavelength (560 nm) using a set of lenses included in the microscope. The resection is thus guided by this fluorescence, the complete disappearance of which will translate into a complete tumour resection. Its interest is twofold: to increase the percentage of complete tumour resection and to improve survival without recurrence and overall survival.Few studies have evaluated the use of fluorescein sodium for the resection of brain tumours (especially glioblastomas) but also cerebral metastases. If two studies on brain metastases showed a complete resection rate greater than 80% and a better rate of local control of brain disease, it is important to note that these studies were not randomised (with a control arm), they did not really prove the effectiveness of this technique under fluorescence, hence the need to set up a randomised study. We therefore propose to evaluate the technique of fluorescence guided microsurgery (fluorescein sodium) compared to the conventional microsurgical technique in the resection of cerebral metastases in adults in order to specify, by a prospective and randomised study, the assistance provided by this technique in the quality of resection and the gain in terms of overall survival and local control of brain disease.
The invention discloses a new compound. The compound is in a colorless oil shape. The molecular formula is C10H12O4, the unsaturation degree is 5, and the structural formula of the compound can be seen in the specification. The ultraviolet spectrum shows that the maximum ultraviolet absorption of the compound is 203 nm. The invention further relates to an extraction and separation method of the compound. Extraction is conducted through ethyl acetate, extraction liquid is separated and purified, and then the monoterpene compound is obtained. Due to the activity effect of the compound on resisting fungi, the lead compound is provided for development of medicine for resisting fungi, and important significance in development of new application of natural products and plant medicine is achieved.
Heterozygous mutations in the TBK1 gene can cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The majority of TBK1-ALS/FTD patients carry deleterious loss-of-expression mutations, and it is still unclear which TBK1 function leads to neurodegeneration. We investigated the impact of the pathogenic TBK1 missense variant p.E696K, which does not abolish protein expression, but leads to a selective loss of TBK1 binding to the autophagy adaptor protein and TBK1 substrate optineurin. Using organelle-specific proteomics, we found that in a knock-in mouse model and human iPSC-derived motor neurons, the p.E696K mutation causes presymptomatic onset of autophagolysosomal dysfunction in neurons precipitating the accumulation of damaged lysosomes. This is followed by a progressive, age-dependent motor neuron disease. Contrary to the phenotype of mice with full Tbk1 knock-out, RIPK/TNF-α-dependent hepatic, neuronal necroptosis, and overt autoinflammation were not detected. Our in vivo results indicate autophagolysosomal dysfunction as a trigger for neurodegeneration and a promising therapeutic target in TBK1-ALS/FTD.
CASE HISTORY: An outbreak of suspected Kikuyu grass (Cenchrus clandestinus) intoxication among dairy cattle occurred on the island of Terceira in the Azores (Portugal), in October 2022. The animals affected were non-lactating dairy cows and heifers from five small farms grazing (free or tethered) a Kikuyu-dominant pasture. Of the 29 animals exposed, 17 were affected, and eight (five heifers and three adult cows) died, resulting in a morbidity rate of 58%, a mortality rate of 28% and a case mortality rate of 47%.
CLINICAL FINDINGS AND TREATMENT: The clinical signs were non-specific and inconsistent, and included dry faeces, some with dark red blood; apathy and prostration; abdominal dilatation; tachycardia; tachypnoea; pale or jaundiced mucous membranes; sham drinking; sialorrhoea; and moderate to severe dehydration. Symptomatic treatment was provided but was ineffective. Haematology and serum biochemistry revealed an acute inflammatory leukogram, increased alkaline phosphatase (ALP) activity, decreased gamma-glutamyl transferase (GGT) activity, and azotaemia.The most consistent necropsy findings were haemorrhages in the epicardium and endocardium, an enlarged liver with rounded edges, non-perforated abomasal ulcers, and haemorrhagic lesions in the small and large intestines. Histopathology indicated myocarditis, hepatitis, interstitial nephritis, enteritis and colitis.Several fungal species were isolated from grass samples taken from affected pastures including several Fusarium spp., the genus implicated in Kikuyu toxicosis. Immediate removal of the animals from the pasture with Kikuyu was the only measure that prevented new cases and resulted in the recovery of some of the less affected animals.
DIAGNOSIS: The epidemiological features of this outbreak and the clinical signs and micro- and macroscopic lesions observed were highly suggestive of Kikuyu grass poisoning.
CLINICAL RELEVANCE: Although the weather conditions varied from other published cases, the grazing conditions (almost exclusive Kikuyu grass) and the post-mortem findings were very similar to those described in the literature, particularly the haemorrhages in the epicardium and endocardium. Kikuyu grass is very invasive and presents many desirable characteristics as cattle feed. Thus, an increase in cases of intoxication may be expected. Practitioners and farmers in areas where Kikuyu grass is abundant should be aware of the potential risks of grazing cattle exclusively on these pastures. They should also be aware of the early and subtle signs of Kikuyu intoxication to allow for timely removal of the animals from pasture.
FIELD: medicine, particularly, stomatology and compositions for teeth cleaning. SUBSTANCE: composition for teeth cleaning contains the first preparation and the second one. The first preparation includes efficient quantity of one or few linear polyphosphates which chain contains on the average four or more molecules, efficient quantity of buffer agent and one or few aqueous carriers. Total content of water in the first preparation is approximately 5-20%. The second preparation includes soluble source of fluorine ions, efficient quantity of buffer agent and one or few aqueous carriers. EFFECT: higher activity; prevention of tartar formation. 10 cl, 5 ex
Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
Immediate release (IR) tramadol has demonstrated efficacy in several pain conditions including: obstetrical, gynecological, orthopedic, abdominal, and oral surgery. The short elimination half-life of IR tramadol necessitates every 4-6 hour dosing to maintain optimum levels of analgesia in chronic pain. The study medication in this study is a once-daily, extended release (ER) tramadol formulation. This study is a multicenter, multiple-dose, 1-year open-label study designed to assess the safety and effectiveness of tramadol HCl ER. Patients with moderate to severe chronic non-malignant pain, requiring treatment with an analgesic on a daily basis, are eligible for study participation. Patients eligible for enrollment are as follows: those who completed 12 weeks in one of two prior double-blind studies ("roll-over patients") or those without participation in any prior study of tramadol HCl ER ("direct enrollment patients"). Following a screening evaluation and baseline assessment, roll-over patients will be treated for up to 38 weeks and direct enrollment patients for up to 58 weeks. At baseline (Visit 2), patients will receive tramadol HCl ER 100 mg once daily (QD) for 3 days; on day 4, they will increase to tramadol HCl ER 200 mg QD, based on tolerability. Patients will be required to be on a minimum dose of tramadol HCl ER 200 mg QD by Visit 3. At Visit 4, patients are required to begin treatment with a minimum dose of tramadol HCl ER 300 mg QD. The maximum dose of tramadol HCl ER for patients \>= 75 years old is 300 mg QD. By Visit 5, patients \< 75 years old are to be initiated on a tramadol HCl ER dose of 400 mg QD. Patients who cannot tolerate a dose increase of tramadol HCl ER from 300 mg or 400 mg QD (due to side effects) or who upon dose increase cannot tolerate the dose will be permitted to reduce the tramadol HCl ER dose to 300 mg QD. Patients unable to tolerate tramadol HCl ER 300 mg or 400 mg QD or those who had pain unresponsive to appropriate dose adjustments will be discontinued and alternate analgesic therapy initiated, as appropriate.
The invention discloses a traditional Chinese medicine capsule for curing psoriasis. The components of the capsule are composed of: 100 grams of licorice root, 150 grams of cotex dictamni, 10 grams of scolopendra, 10 grams of scorpion, 30 grams of calomel, 100 grams of Chinese angelica, 100 grams of glabrous greenbrier rhizome, 150 grams of Japanese pagodatree flower-bud, and 60 grams of natural indigo. The medicinal materials are respectively ground into powder, mixed evenly and put into capsules. The prescription is reasonable, with high efficacy and quick effect. The psoriasis can be cured within a single course of treatment (30 days) and is not liable to relapse, and the recurrence rate is only 3 percent. The capsule has the efficacies of removing and stopping itch, nourishing blood, moistening skin, eliminating sores and tumescence, curing rheumatism, and cleaning heat and toxin, is applicable to cure skin diseases, such as psoriasis, tinea capitis, foot and hand tinea, tinea corporis, and the like.
NEW MATERIAL:A compound expressed by formula I [X is H, halogen, lower alkyl, cycloalkyl, lower alkoxy, benzyl, phenylthio or phenyl which may have a substituent group (halogen or CH3); Y is lower alkyl or acyl; R is H or lower alkyl; n is 1 or 2]. EXAMPLE:3-Acetylthiomethyl-3-benzoylpropionic acid. USE:A remedy for autoimmune diseases, e.g. chronic rheumarthritis, systemic lupus erythematosus, etc., and diseases caused by immunological function insufficiency, e.g. cancer, microbism, asthma, etc. PREPARATION:A compound expressed by formula I is reacted with formaldehyde in pyridine in the presence of a secondary amine to give a compound expressed by formula III, which is then reacted with a compound expressed by the formula YSH in an organic solvent to afford the compound expressed by formula I (R is H). Furthermore, the resultant compound, as desired, is reacted with a normally used alkylating agent in an organic solvent in the presence of a base to provide the compound expressed by formula I (R is lower alkyl).
PROBLEM TO BE SOLVED: To provide a screening method of a material capable of modulating bioactivation of a biological material by identifying the biological material concerned with the modulation such as osteoplasty (or chondrogenesis) and differentiation of osteoblast (or chondrocyte), to provide a medicine having excellent prophylactic and therapeutic effects on bone disease. SOLUTION: This method for screening the compound having activities on the bone comprises using an NRH: quinone oxidoreductase (NQO2), a partial peptide thereof or a salt thereof. The bone agonist contains the compound obtained by the method. The method for preventing and treating the human or mammal bone disease comprises inhibiting or promoting the expression or activity of the NQO2. The polynucleotide encodes the NQO2 or the partial peptide thereof. The diagnostic agent of the bone disease contains an antibody having specific affinity to the NQO2, or the partial peptide or the salt thereof.
The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 μm and 5 μm, preferably between 0.2 μm and 2.0 μm, and the median aerodynamic mass diameter of aerosol particles comprising the liposomes is between 1 μm and 6 μm, preferably between 1.5 μm and 5 μm, in particular preferably between 2 μm and 4.5 μm. It is further in particular advantageous if the liposomes comprise an atomization stability of greater than 50%, preferably greater than 75%, in particular preferably greater than 80%, and if the transition temperature is greater than 37° C., preferably greater than 45° C., in particular preferably greater than 50° C.
This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
The ACL stabilizes the knee joint by preventing the shinbone (tibia) from sliding forward beneath the thighbone (femur). A hard twist or excessive pressure on the ACL can tear or rupture the ligament, resulting in high levels of short-term disability and extensive rehabilitation. Previous data indicate that women who participate in sports or who are otherwise physically active have higher rates of ACL injury than men; the reason for this is unknown. There are four groups of potential risk factors for ACL injury: environmental, anatomical, hormonal, and biomechanical or neuromuscular. In particular, poor technique when landing from a jump (also known as jump-landing) is proposed as a specific neuromuscular risk factor of interest in this study. This study will determine gender-specific anatomical, hormonal, and demographic risk factors for ACL injury, as well as quantify gender-specific differences in jump-landing technique and other neuromuscular risk factors.

This observational cohort study will enroll 4,800 cadets at the three large U.S. military academies; approximately 50% of those enrolled will be women. Only incoming cadets at the U.S. Naval, Air Force, or Military Academies will be able to participate. Each study participant will undergo a baseline assessment that will include measurement of neuromuscular risk factors using motion analysis, strength testing, and standardized assessment of poor jump-landing technique using the Landing Error Score System (LESS). All participants will be followed for up to 4 years. ACL injuries will be prospectively identified; an injury questionnaire is administered to participants who sustain an ACL injury while they are cadets. Otherwise, there is no further contact.
Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to \< 50 kg received 37.5 mg; ≥50 kg and \< 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.